Recent papers and workshops from the FDA have proposed focusing on measurement of three concepts in cancer clinical trials for label claims: symptomatic adverse effects (AEs), physical function (PF), and disease-related symptoms. Responding to these recommendations for use of PROs, the EORTC proposes a new model allowing for an assessment strategy within one measurement system. Within the FDA’s framework, one should select key endpoints with well-defined objectives, and determine disease-related symptoms and AEs from previous research, literature, and qualitative methods, before choosing appropriate PRO measures. This abstract shows how the EORTC’s tools can meet this selection. The EORTC QLQ-C30 core questionnaire measures PF, as well as other well-defined functions (role, emotional, social, cognitive), and includes 11 out of 12 core set cancer symptoms (Reeve 2014). As a holistic instrument to measure HRQOL, it covers some symptoms and AEs (appetite loss, fatigue, nausea, vomiting, dyspnea, diarrhea, constipation, insomnia), and additional domains: overall QOL and financial difficulties. A shorter 17-item QLQ-F17 is available, focusing on function only. Alternatively, all QLQ-C30 domains (including PF) can be measured with an IRT-based Computer Adaptive Testing (CAT) system with full item banks or short forms for higher precision or more flexibility. Other disease-related symptoms and most frequent AEs are part of the validated disease-specific modules. Any missing issues can be included in a supplemental item list created with the Item Library’s over 950 items. Through mixing static questionnaires with item lists to address possible gaps, EORTC’s one system solution allows for a consistent measurement strategy with less cognitive burden than when various instruments are combined. The wide range of over 40 validated EORTC instruments and Item Library enables a flexible assessment tailored to each trial’s objectives. We believe such a system will fulfill the FDA’s and other regulators’ strategy for selecting robust endpoints in clinical trials.